Magic mushroom compound tested as One-Time depression fix for cancer patients
NCT ID NCT06319378
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a single 25 mg dose of psilocybin can relieve major depression in 100 adults with cancer, compared to a very low 1 mg dose. Participants must be 20–80 years old, have had depression for at least a month after their cancer diagnosis, and stop other antidepressants before the trial. The main goal is to measure changes in depression scores 42 days after the dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
psilocybin
What this could lead to
If successful, this could point toward a new, fast-acting treatment for depression in people with cancer, potentially easing severe mood symptoms with just one dose.
What could go wrong
This is a Phase 2 trial with only 100 participants, so results are preliminary. Psilocybin can cause temporary anxiety, confusion, or nausea, and its long-term safety in this population is not yet known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Norra Stockholms Psykiatri
RECRUITINGStockholm, Stockholm County, Sweden
Contact
Contact Email: •••••@•••••
-
Psykiatriska Kliniken, Akademiska Sjukhuset
RECRUITINGUppsala, Uppsala County, Sweden
Contact Email: •••••@•••••
Contact
-
region Västra Götaland
RECRUITINGGothenburg, Göteborg, Sweden
Contact Email: •••••@•••••
Contact
-
Örebro sjukhus
RECRUITINGÖrebro, Örebro County, Sweden
Contact
Contact Email: •••••@•••••
Contact